TINT250117C41000
- 0.00
- 0.000.00%
PROSHARES SMART MATERIALS ETF Newsroom
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday
Takeda-backed Ascentage Pharma Files for $100M IPO
Sangamo Says Collaboration, License Agreement With Pfizer On Giroctocogene Fitelparvovec Will Terminate Effective April 21, 2025; Plans To Explore All Options To Commercialize The Asset, Including Seeking Potential New Partner
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
The US stock market is expected to reach new highs in 2025. How to seize the opportunity? The three most loved Index component stocks on Wall Street have been revealed!
Bank of America stated that technology giants are likely to continue outperforming the Large Cap by 2025. The bank's derivatives Analyst, Benjamin Bowler, explained that interest rate cuts and the ongoing AI boom could lead to further gains for large technology companies in the United States.
Peering Into First Solar's Recent Short Interest
10 Health Care Stocks With Whale Alerts In Today's Session
10 Industrials Stocks With Whale Alerts In Today's Session
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
Pfizer (PFE.US) cancer small molecule combination therapy has received accelerated approval from the FDA.
Pfizer (PFE.US) recently announced that the USA FDA has expedited the approval of the BRAF inhibitor Braftovi (encorafenib) in combination with Erbitux (cetuximab) and the mFOLFOX6 treatment regimen (which includes fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been tested positive for the BRAF V600E mutation.
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
ProShares Smart Materials ETF Declares Quarterly Distribution of $0.0851
2024's 'Biggest Loses' That Could See Reversal in 2025
Big news in the photovoltaic industry! The Biden administration is reportedly considering reducing tariffs on CECEP Solar Energy equipment from Mexico.
If Biden exempts tariffs, the sustainability of his policy is in doubt, as Trump threatens to impose a 25% tariff on Canada and Mexico, and US manufacturers are lobbying for increased tax-exempt quotas.
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs